Analyst Price Targets — RNA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 18, 2025 2:12 pm | — | Evercore ISI | $72.00 | $72.11 | TheFly | Avidity Biosciences downgraded to In Line from Outperform at Evercore ISI |
| October 28, 2025 8:21 am | Keay Nakae | Chardan Capital | $72.00 | $70.00 | TheFly | Avidity Biosciences downgraded to Neutral from Buy at Chardan |
| October 28, 2025 7:26 am | Luca Issi | RBC Capital | $72.00 | $70.00 | StreetInsider | RBC Capital Downgrades Avidity Biosciences (RNA) to Sector Perform |
| October 28, 2025 7:24 am | Keay Nakae | Loop Capital Markets | $72.00 | $70.00 | StreetInsider | Chardan Capital Markets Downgrades Avidity Biosciences (RNA) to Neutral |
| October 27, 2025 2:42 pm | Market Perform | Leerink Partners | $72.00 | $69.95 | TheFly | Avidity Biosciences downgraded to Market Perform from Outperform at Leerink |
| October 27, 2025 11:20 am | Boobalan Pachaiyappan | Roth Capital | $72.00 | $49.15 | TheFly | Avidity Biosciences downgraded to Neutral from Buy at Roth Capital |
| October 27, 2025 10:43 am | Market Perform | Bernstein | $72.00 | $49.15 | TheFly | Avidity Biosciences downgraded to Market Perform from Outperform at Bernstein |
| October 27, 2025 10:21 am | — | H.C. Wainwright | $72.00 | $49.15 | TheFly | Avidity Biosciences downgraded to Neutral from Buy at H.C. Wainwright |
| September 17, 2025 8:25 am | — | Roth Capital | $62.00 | $40.06 | TheFly | Avidity Biosciences initiated with a Buy at Roth Capital |
| September 10, 2025 1:46 pm | Eric Schmidt | Cantor Fitzgerald | $96.00 | $46.40 | TheFly | Avidity del-zota data 'highly encouraging,' says Cantor Fitzgerald |
Latest News for RNA
Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectively SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) launched today as a newly independent, publicly traded company…
SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that the company will be presenting one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical &…
SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that it intends to convene its upcoming special meeting of stockholders (the "Special Meeting") scheduled for February 23, 2026, at…
Fiera Capital Corp lifted its position in shares of Avidity Biosciences, Inc. (NASDAQ: RNA) by 53.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,202,384 shares of the biotechnology company's stock after purchasing an additional 420,476 shares during the period. Fiera
Del-desiran effectively delivered siRNA to muscle, resulting in approximately 40% mean reduction in DMPK mRNA and amelioration of missplicing Treatment demonstrated improvements in multiple measures including myotonia, muscle function and strength, mobility and patient-reported outcomes Del-desiran showed acceptable safety and tolerability with most adverse events mild or moderate SAN DIEGO, Feb. 18, 2026…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RNA.
U.S. House Trading
No House trades found for RNA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.